Jefferies Financial Group Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $10.00 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 134.19% from the stock’s current price.

A number of other brokerages have also weighed in on PYXS. BTIG Research began coverage on Pyxis Oncology in a research report on Friday, February 9th. They set a “buy” rating and a $8.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, March 22nd. Leerink Partnrs reissued an “outperform” rating on shares of Pyxis Oncology in a research report on Tuesday, January 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Wednesday, April 10th. Finally, SVB Leerink initiated coverage on Pyxis Oncology in a report on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $8.80.

Pyxis Oncology Stock Performance

PYXS stock opened at $4.27 on Tuesday. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The company has a fifty day moving average price of $5.00 and a 200-day moving average price of $3.39. The company has a market capitalization of $251.42 million, a P/E ratio of -2.32 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. As a group, sell-side analysts forecast that Pyxis Oncology will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC bought a new position in Pyxis Oncology during the 3rd quarter worth approximately $26,000. Acadian Asset Management LLC purchased a new stake in shares of Pyxis Oncology during the third quarter valued at approximately $26,000. Schulhoff & Co. Inc. bought a new position in shares of Pyxis Oncology in the third quarter worth approximately $44,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology in the first quarter worth $59,000. Finally, Radcliffe Capital Management L.P. bought a new stake in Pyxis Oncology during the 3rd quarter valued at $106,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.